Evidence map›Paper›PMID 35530162›Full record

ReviewActa pharmaceutica Sinica. B2022

Emerging role of natural products in cancer immunotherapy.

Songtao Dong, Xiangnan Guo, Fei Han, Zhonggui He, Yongjun Wang

Open access · diamondAbstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 249 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Therapeutic Effects ofInternational journal of molecular sciences · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Songtao DongDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Xiangnan GuoDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Fei HanSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhonggui HeDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yongjun WangDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy has become a new generation of anti-tumor treatment, but its indications still focus on several types of tumors that are sensitive to the immune system. Therefore, effective strategies that can expand its indications and enhance its efficiency become the key element for the further development of cancer immunotherapy. Natural products are reported to have this effect on cancer immunotherapy, including cancer vaccines, immune-check points inhibitors, and adoptive immune-cells therapy. And the mechanism of that is mainly attributed to the remodeling of the tumor-immunosuppressive microenvironment, which is the key factor that assists tumor to avoid the recognition and attack from immune system and cancer immunotherapy. Therefore, this review summarizes and concludes the natural products that reportedly improve cancer immunotherapy and investigates the mechanism. And we found that saponins, polysaccharides, and flavonoids are mainly three categories of natural products, which reflected significant effects combined with cancer immunotherapy through reversing the tumor-immunosuppressive microenvironment. Besides, this review also collected the studies about nano-technology used to improve the disadvantages of natural products. All of these studies showed the great potential of natural products in cancer immunotherapy.

Indexed as

Adoptive immune-cells transfer immunotherapyAKT, alpha-serine/threonine-specific protein kinaseB2M, beta-2-microglobulinbFGF, basic fibroblast growth factorBMDCs, bone marrow dendritic cellsBPS, basil polysaccharideBTLA, B- and T-lymphocyte attenuatorCAFs, cancer-associated fibroblastsCancer immunotherapyCancer vaccinesCCL22, C–C motif chemokine 22CIKs, cytokine-induced killer cellsCOX-2, cyclooxygenase-2CRC, colorectal cancerCTLA-4, cytotoxic T lymphocyte antigen-4CTL, cytotoxic T cellDAMPs, damage-associated molecular patternsDCs, dendritic cellsFDA, US Food and Drug AdministrationHCC, hepatocellular carcinomaHER-2, human epidermal growth factor receptor-2HIF-1α, hypoxia-inducible factor-1αHMGB1, high-mobility group box 1HSPs, heat shock proteinsICD, Immunogenic cell deathICTs, immunological checkpointsIFN-γ, interferon γIL-10, interleukin-10Immuno-check pointsImmunosuppressive microenvironmentLLC, Lewis lung cancerMcl-1, myeloid leukemia cell differentiation protein 1MDSCs, myeloid-derived suppressor cellsMHC, major histocompatibility complex classMITF, melanogenesis associated transcription factorMMP-9, matrix metalloprotein-9mTOR, mechanistic target of rapamycinNatural productsNF-κB, nuclear factor kappa-light-chain-enhancer of activated B cellsNKTs, natural killer T cellsNSCLC, non-small cell lung cancerOVA, ovalbuminPD-1, programmed death-1PD-L1, programmed death receptor ligand 1PGE-2, prostaglandin E2PI3K, phosphoinositide 3-kinaseROS, reactive oxygen speciesSTAT3, signal transducer and activator of transcription 3TAMs, tumor-associated macrophagesTAP, transporters related with antigen processingTeffs, effective T cellsTGF-β, transforming growth factor-βTh1, T helper type 1TILs, tumor infiltration lymphocytesTLR, Toll-like receptorTNF-α, tumor necrosis factor αTregs, regulatory T cellsTSA, tumor specific antigensVEGF, vascular endothelial growth factor

Identifiers

PMID35530162
PMCPMC9069318
OpenAlexW3195008613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.